ANG 4043
Alternative Names: ANG-4043Latest Information Update: 23 Oct 2022
At a glance
- Originator AngioChem
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies; Peptide drug conjugates
- Mechanism of Action ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Brain metastases
Most Recent Events
- 12 Sep 2022 ANG 4043 is available for licensing as of 12 Sep 2022. http://angiochem.com/partnering
- 07 Sep 2022 Preclinical trials in Brain metastases in Canada (Parenteral) (AngioChem pipeline, September 2022)
- 07 Sep 2022 Pharmacodynamics data from a preclinical trial in Brain metastases released by AngioChem (AngioChem pipeline, September 2022)